JP2021531312A - 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体 - Google Patents

抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体 Download PDF

Info

Publication number
JP2021531312A
JP2021531312A JP2021504238A JP2021504238A JP2021531312A JP 2021531312 A JP2021531312 A JP 2021531312A JP 2021504238 A JP2021504238 A JP 2021504238A JP 2021504238 A JP2021504238 A JP 2021504238A JP 2021531312 A JP2021531312 A JP 2021531312A
Authority
JP
Japan
Prior art keywords
zanamivir
conjugate
cells
influenza virus
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021504238A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020023323A5 (https=
JP2021531312A5 (https=
Inventor
フィリップ スチュアート ロウ
シン リュウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of JP2021531312A publication Critical patent/JP2021531312A/ja
Publication of JPWO2020023323A5 publication Critical patent/JPWO2020023323A5/ja
Publication of JP2021531312A5 publication Critical patent/JP2021531312A5/ja
Priority to JP2023212681A priority Critical patent/JP2024029005A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2021504238A 2018-07-26 2019-07-20 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体 Pending JP2021531312A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023212681A JP2024029005A (ja) 2018-07-26 2023-12-18 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862703534P 2018-07-26 2018-07-26
US62/703,534 2018-07-26
US201962846549P 2019-05-10 2019-05-10
US62/846,549 2019-05-10
PCT/US2019/042715 WO2020023323A1 (en) 2018-07-26 2019-07-20 Small molecule ligand-targeted drug conjugates for anti-influenza chemotherapy and immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023212681A Division JP2024029005A (ja) 2018-07-26 2023-12-18 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体

Publications (3)

Publication Number Publication Date
JP2021531312A true JP2021531312A (ja) 2021-11-18
JPWO2020023323A5 JPWO2020023323A5 (https=) 2022-07-26
JP2021531312A5 JP2021531312A5 (https=) 2022-07-26

Family

ID=69180703

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021504238A Pending JP2021531312A (ja) 2018-07-26 2019-07-20 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体
JP2023212681A Pending JP2024029005A (ja) 2018-07-26 2023-12-18 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023212681A Pending JP2024029005A (ja) 2018-07-26 2023-12-18 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体

Country Status (7)

Country Link
US (1) US20210393786A1 (https=)
EP (1) EP3826681A4 (https=)
JP (2) JP2021531312A (https=)
CN (1) CN112672762B (https=)
AU (1) AU2019312144B2 (https=)
CA (1) CA3107778A1 (https=)
WO (1) WO2020023323A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021210987A1 (en) * 2020-01-24 2022-08-04 Regeneron Pharmaceuticals, Inc. Protein-antiviral compound conjugates
US20210402001A1 (en) * 2020-06-30 2021-12-30 David I. Cohen Zinc Porters, and their Monoclonal Antibody Conjugates, for the Prevention and Treatment of COVID-19 (SARS-CoV-2), Other Infections, and Cancers
EP4175637A4 (en) * 2020-07-02 2024-08-07 Purdue Research Foundation Tetrahydro-3h-pyrazolo quinolone and tetrahydro-3h-pyrrolo[3,2-f]quinoline-containing compounds and uses thereof
WO2022015754A2 (en) * 2020-07-13 2022-01-20 University Of Southern California Universal car-nk cell targeting various epitopes of hiv-1 gp160
EP4337663A4 (en) * 2021-05-14 2026-04-15 Purdue Research Foundation BISPECIFIC SMALL MOLECULE-BASED IMMUNE CELL ATTACHMENTS AND THEIR USE IN THE TREATMENT OF ENVELOPED VIRUS INFECTION
MX2024000897A (es) * 2021-07-28 2024-02-06 Regeneron Pharma Conjugados de proteina y compuestos antivirales.
CN119403574A (zh) * 2022-04-19 2025-02-07 普渡研究基金会 双半抗原和三半抗原缀合物、组合物、制备方法及其治疗方法
CN116375647A (zh) * 2023-01-21 2023-07-04 兰州大学 一种基于Click反应的CAR-T细胞药物递送平台及其构建方法与应用
WO2025085664A1 (en) * 2023-10-17 2025-04-24 Mary Lynn Niedrauer Conjugates, com positions and methods for treating influenza
WO2025133395A1 (en) 2023-12-22 2025-06-26 Forx Therapeutics Ag Bicyclic (hetero)arylene wrn inhibitory compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534388A (ja) * 2000-06-02 2003-11-18 ボード・オブ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム エチレンジシステイン（ｅｃ）−薬物結合体
JP2013528160A (ja) * 2010-05-10 2013-07-08 アカデミア シニカ 抗インフルエンザ活性を有するザナミビルホスホネート同族体およびインフルエンザウイルスのオセルタミビルに対する感受性の決定

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6692724B1 (en) * 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
WO2002028411A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Compounds for sustained release of orally delivered drugs
CN102036658A (zh) * 2008-05-23 2011-04-27 香港大学 治疗流感的联合疗法
CA2790577A1 (en) * 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9250238B2 (en) * 2010-06-25 2016-02-02 Purdue Research Foundation Pathogen detection
US10130714B2 (en) * 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
EP2934532B1 (en) * 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US10975112B2 (en) * 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
JP7282521B2 (ja) * 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534388A (ja) * 2000-06-02 2003-11-18 ボード・オブ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム エチレンジシステイン（ｅｃ）−薬物結合体
JP2013528160A (ja) * 2010-05-10 2013-07-08 アカデミア シニカ 抗インフルエンザ活性を有するザナミビルホスホネート同族体およびインフルエンザウイルスのオセルタミビルに対する感受性の決定

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Synergistic Effect of Zanamivir-Porphyrin Conjugates on Inhibition of Neuraminidase and Inactivation", JOURNAL OF MEDICINAL CHEMISTRY, vol. 52, no. 15, JPN6023024572, 13 August 2009 (2009-08-13), pages 4903 - 4910, ISSN: 0005269850 *

Also Published As

Publication number Publication date
CA3107778A1 (en) 2020-01-30
JP2024029005A (ja) 2024-03-05
EP3826681A1 (en) 2021-06-02
AU2019312144B2 (en) 2025-05-08
WO2020023323A1 (en) 2020-01-30
US20210393786A1 (en) 2021-12-23
EP3826681A4 (en) 2022-08-17
CN112672762B (zh) 2025-06-13
AU2019312144A1 (en) 2021-03-18
CN112672762A (zh) 2021-04-16

Similar Documents

Publication Publication Date Title
JP2021531312A (ja) 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体
AU2018218179B2 (en) Methods of treating influenza
Hendricks et al. Sialylneolacto-N-tetraose c (LSTc)-bearing liposomal decoys capture influenza A virus
Liu et al. A universal dual mechanism immunotherapy for the treatment of influenza virus infections
Liao et al. Germacrone inhibits early stages of influenza virus infection
Wu et al. Progress of small molecular inhibitors in the development of anti-influenza virus agents
Song et al. Biological evaluation of anti-influenza viral activity of semi-synthetic catechin derivatives
Meseko et al. Antiviral options and therapeutics against influenza: history, latest developments and future prospects
Dong et al. γδ T cells provide protective function in highly pathogenic avian H5N1 influenza A virus infection
Lin et al. Potent influenza A virus entry inhibitors targeting a conserved region of hemagglutinin
Hussein et al. Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus
JP2015166396A (ja) 標的化された広域スペクトルのインフルエンザ中和のための操作されたポリペプチド剤
Jin et al. Toosendanin from melia fructus suppresses influenza A virus infection by altering nuclear localization of viral polymerase PA protein
Tian et al. Dihydromyricetin is a new inhibitor of influenza polymerase PB2 subunit and influenza-induced inflammation
CN104151403B (zh) 一类多肽或其衍生物、及其在流感病毒感染中的应用
US20230099027A1 (en) Virucidal compositions and use thereof
Sriwilaijaroen et al. 6SLN-lipo PGA specifically catches (coats) human influenza virus and synergizes neuraminidase-targeting drugs for human influenza therapeutic potential
Xu et al. Inhibition of peptide BF-30 on influenza A virus infection in vitro/vivo by causing virion membrane fusion
Lv et al. Zanamivir–cholesterol conjugate: a long-acting neuraminidase inhibitor with potent efficacy against drug-resistant influenza viruses
Chen et al. The seafood Musculus senhousei shows anti-influenza A virus activity by targeting virion envelope lipids
Yang et al. Influenza virus entry inhibitors
Liu et al. Design of neuraminidase-targeted imaging and therapeutic agents for the diagnosis and treatment of influenza virus infections
Lau et al. Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice
TWI333959B (en) Methods and reagents for the analysis and purification of polysaccharides
Li et al. A small molecule compound targeting hemagglutinin inhibits influenza A virus and exhibits broad-spectrum antiviral activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230907

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240227